Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by HC Wainwright

HC Wainwright initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm issued a sell rating and a $80.00 price objective on the biotechnology company’s stock.

SRPT has been the subject of several other research reports. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Citigroup cut their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.73.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $114.65 on Monday. Sarepta Therapeutics has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The company has a market capitalization of $10.95 billion, a price-to-earnings ratio of 91.72 and a beta of 0.81. The firm has a 50-day simple moving average of $121.80 and a 200-day simple moving average of $131.40. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently made changes to their positions in SRPT. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth $31,000. New Covenant Trust Company N.A. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $32,000. Sunbelt Securities Inc. increased its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank increased its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Finally, Nkcfo LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth about $43,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.